What a price index is for
A single quote carries no information about whether it is reasonable. An index of observed prices across suppliers gives a range, and a range is what turns a number into a judgement.
It is most useful at the extremes. A quote well above the range calls for an explanation, usually higher purity, a different salt form or more extensive analysis. A quote well below it calls for a closer look at the documentation.
What drives the price of a peptide
Length is the largest factor. Solid-phase synthesis adds one residue at a time, and yield compounds down with each coupling, so a 40 residue peptide costs far more than four times a 10 residue one.
Difficult sequences cost more again: hydrophobic stretches aggregate on the resin and couple poorly, beta-branched residues are slow, and disulfide-containing peptides need a folding step with its own yield. Demand matters too, since a peptide made at scale is cheaper per milligram than one made to order.
- •Sequence length: the dominant factor
- •Sequence difficulty: aggregation-prone stretches and beta-branched residues
- •Purity specification: reaching 99 percent costs more than reaching 95
- •Salt form: acetate requires an exchange step
- •Modifications: cyclisation, lipidation and labelling each add steps
- •Scale and demand: made-to-order costs more per milligram than made in bulk
Reading the value rating
The rating compares an observed price against the range for that compound, so it is a relative statement rather than an assessment of the product. A well-documented peptide at the top of its range may be better value than an undocumented one at the bottom.
It says nothing about purity, salt form or analysis, and those are what separate two offers at the same price. Use the rating to identify which offers are worth investigating, then investigate them.
Why the figures move
Peptide pricing shifts with raw material costs, manufacturing capacity, demand and currency. Figures more than a few months old should be treated as historical context rather than as current market rates.
Regulatory attention moves prices too, sometimes sharply, and often more through supply availability than through cost of production.
How the price index is compiled
Observed prices from publicly listed offers, normalised to cost per milligram and expressed as a range with a value rating against it.
- Collect listed prices. From publicly available supplier listings, recording the vial size, quantity and any stated purity so the entries are comparable.
- Normalise to cost per milligram. Total price over total labelled mass. This is the figure that survives differences in vial size.
- Express as a range. A range rather than an average, because the spread is the informative part. A wide spread indicates a market where documentation and purity vary substantially.
- Rate a given price against the range. Where an individual quote sits relative to the observed distribution for that compound.
- Date the observations. Prices move. An undated price index is a historical document presented as a current one.
What this method cannot tell you
- •It reflects listed prices, not negotiated ones, and bulk pricing is frequently well below list.
- •It normalises to labelled mass, not to peptide mass. Purity and salt form differences are not corrected.
- •It is a snapshot. Peptide pricing moves with capacity, demand and currency.
- •A price cannot be assessed without the documentation behind it. The index identifies offers worth investigating, not offers worth buying.
Peptide price index: frequently asked questions
A record of observed market prices for common peptides, normalised to cost per milligram, so an individual quote can be judged against a range.
Because synthesis difficulty, purity specification, salt form, included analysis and scale all differ, and each of them moves the price substantially.
A sequence that aggregates on the resin can cost several times what a similar-length easy sequence costs.
In rough order of impact:
- •Length, because coupling yields compound down with every residue
- •Difficult sequences that aggregate or couple slowly
- •A higher purity specification
- •Modifications: cyclisation, lipidation, labelling
- •Small scale, since fixed costs are spread across less material
It is a reason to look at the documentation before deciding. The cheapest corner to cut in peptide production is the analysis.
Check for a batch-specific certificate from an independent laboratory, and check what purity method it reports.
Not necessarily. Higher purity, an acetate salt form, more extensive analysis and better documentation all cost more to provide.
The question is whether the premium buys something you need.
They are a dated snapshot of listed prices. Peptide pricing moves with capacity, demand and currency, so anything more than a few months old is historical context.
No. They are normalised to labelled mass, so two entries at the same price per milligram may differ in actual peptide content.
Correcting with the net peptide content calculator is what makes a like-for-like comparison.
Because coupling efficiency compounds. At 99.5 percent per step, a 50 residue peptide completes correctly in 78 percent of chains, and the rest have to be separated out.
That means lower yield and harder purification simultaneously, which is why cost rises faster than length.
Usually substantially, because the fixed costs of a synthesis are spread across more material.
The saving is real only if the material is used within its shelf life.
Price and quality correlate loosely and not reliably. Some low-cost suppliers document well and some expensive ones do not.
The certificate is the evidence either way, which is why documentation quality is the threshold rather than price.
Yes. Salt exchange is an additional processing step that costs time and loses material.
The acetate form also carries more peptide per milligram, so part of the premium comes back as content.
Sharply, and more often through availability than through cost of production. Enforcement action against suppliers reduces supply, and reduced supply raises prices.
Sources: FDA warning letters database
There is no general answer. The right comparison is against the observed range for that specific compound.
Listed prices generally do not. Shipping, cold chain and customs attach to the order and can be a substantial fraction of a small one.
To identify quotes that are unusual in either direction, then investigate those. It sorts offers into worth looking at and not, rather than into good and bad.
Import duty, local regulation, currency and market size all differ. Regulatory status has the largest effect where it restricts who may supply.
The regulatory status checker summarises where each compound stands in the major jurisdictions.
Related Products
Related Research News
Bachem Stock Rises as Investors Weigh Strong Half-Year Results
Bachem shares moved higher as investors assessed the company's strong half-year figures. The Swiss peptide manufacturer drew market attention following the release of its latest results, with the stock gaining ground as shareholders digested the numbers.
How to Tell a Legitimate Compounded GLP-1 Provider From a Risky One: Today News
A new USA Today report outlines how patients and researchers can separate legitimate compounded GLP-1 providers from risky operators. The guidance arrives as demand for compounded semaglutide and tirzepatide remains high and quality standards vary widely across the market.
Retatrutide in Canada: Research Access and Regulatory Status
Retatrutide is an investigational triple agonist with no documented Canadian market authorization. This page separates peer-reviewed findings from supplier claims and unverified listings.